[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sundaram, 2017 - Google Patents

Sialic acid and its analogues as potential neuro anti-inflammatory therapeutic candidates for Alzheimer's

Sundaram, 2017

View PDF
Document ID
1923887007845111152
Author
Sundaram P
Publication year
Publication venue
Brain

External Links

Snippet

Post-translationally modified human β-amyloid (Aβ) is found to be a potent target for drug development. Implication of glycosylation, more particularly sialylation as identified with tyrosine at position ten (Y10) in the Aβ appears to play a role in pathogenesis of Alzheimer's …
Continue reading at www.siriusstore.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
EP2052085B1 (en) Methods for modulating set and uses thereof
Sun et al. Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21
Holtzman et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease
EP0890105B1 (en) Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
Takada et al. Molecular mechanism of apoptosis by amyloid β-protein fibrils formed on neuronal cells
Waragai et al. Importance of adiponectin activity in the pathogenesis of Alzheimer's disease
Yong et al. Neuroprotective effects of lactoferrin in Alzheimer’s and Parkinson’s diseases: A narrative review
Bhatti et al. Targeting dynamin-related protein-1 as a potential therapeutic approach for mitochondrial dysfunction in Alzheimer's disease
Ko et al. The role of TLR4 and Fyn interaction on lipopolysaccharide-stimulated PAI-1 expression in astrocytes
CN105061560A (en) Nogo-A receptor binding peptide as well as derivative and application thereof
Sharma et al. Effect of disease-associated P123H and V70M mutations on β-synuclein fibrillation
Sciacca et al. Semax, a synthetic regulatory peptide, affects copper-induced abeta aggregation and amyloid formation in artificial membrane models
Ayyubova Apoe4 is A risk factor and potential therapeutic target for alzheimer's disease
Palihati et al. Clusterin is a potential therapeutic target in Alzheimer’s disease
Kanyenda et al. The dynamics of CD147 in Alzheimer's disease development and pathology
Sundaram Sialic acid and its analogues as potential neuro anti-inflammatory therapeutic candidates for Alzheimer’s
Minami et al. ApoE mimetic peptide decreases Aβ production in vitro and in vivo
US20030004107A1 (en) Method of preventing cell death using segments of neural thread proteins
Poblano et al. Drugs targeting APOE4 that regulate beta‐amyloid aggregation in the brain: therapeutic potential for Alzheimer's disease
US20140030274A1 (en) Amyloidosis target useful in methods of treatment and for screening of compounds
CN111617232B (en) Application of ApoE receptor protein short peptide blocker in Alzheimer disease
US20230002458A1 (en) Compound and method for treatment of alzheimer's disease
Lin et al. Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer’s Disease
Guo et al. Diabetes mellitus and Alzheimer's disease: Vacuolar adenosine triphosphatase as a potential link
US9045525B2 (en) Amyloid β-protein-specific production-inhibiting polypeptide